	US 11,896,682 B2
	Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
Marcus Kelly, New York, NY (US); Dangshe Ma, Millwood, NY (US); and William Olson, Yorktown Heights, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed on Sep. 15, 2020, as Appl. No. 17/021,497.
Claims priority of provisional application 62/901,003, filed on Sep. 16, 2019.
Prior Publication US 2021/0077638 A1, Mar. 18, 2021
Int. Cl. A61K 51/10 (2006.01); C07K 16/28 (2006.01)

CPC A61K 51/103 (2013.01) [C07K 16/2863 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

47 Claims

1. A radiolabeled antibody conjugate comprising:

(a) an antibody or antigen-binding fragment thereof that binds MET, wherein the antibody or antigen-binding fragment thereof comprises: (i) three heavy chain complementarity determining regions (HCDRs) in a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122, and 130; and (ii) three light chain complementarity determining regions (LCDRs) in a light chain variable region (LCVR) having an amino acid sequence of SEQ ID NO: 138,

(b) a chelating moiety, and